Follow along with the video below to see how to install our site as a web app on your home screen.
Note: This feature currently requires accessing the site using the built-in Safari browser.
You are using an out of date browser. It may not display this or other websites correctly. You should upgrade or use an alternative browser.
Mon news: AZ obesity pill. 50% of drug shortages last at least 2 years. Pharmas and IRA lawsuit appeals. Novo-Ascendis biobucks deal. Wegovy reduces all-cause hospital admissions. See more on our front page
http://alph.st/ba1df6ff Higher sales of Revlimid and Otezla help Celgene to report better than expected sales figure. Will the two (Impact and Juno) multi-billion dollar acquisitions help the struggling Celgene in 2018 and beyond?
anonymous
Thread
cancer
cancer treatment
celgene
earnings
junotherapeutics
otezla
outlook
revlimid
tax reform
It's an M&A Monday for the pharma companies. Two major pharma acquisitions announced today.
1) Celgene acquires Juno for $9 billion http://alph.st/pd7bf702
2) Sanofi acquires Bioverative for $11.6 billion
Last week, there was a rumor that Celgene's acquisition of Juno and also news about...
anonymous
Thread
acquisition
bioverative
buyout
cancer
cancer treatment
celgene
junotherapeutics
m&a
revlimid
sanofi
Yesterday, WSJ has stated that Celgene is holding talks to acquire Juno Therapeutics. http://alph.st/pd7bf702
Will this move strengthen Celgene? In 2018, the first acquisition was Impact and now the unconfirmed Juno hunting.
anonymous
Thread
acquisition
buyout
cancer
cancer treatment
celgene
junotherapeutics
rumor
Celgene announces positive results from the trials with its development partners Bluebird Bio and Juno Therapeutics in ASH 2017.
I think it's an advantage for all the three companies involved; especially for Bluebird Bio.
anonymous
Thread
american society of hematology
bluebird bio
cancer
cancer treatment
celgene
junotherapeutics
lymphoma
myeloma
partnership